Comparable stake leader
BlackRock, Inc.
SEC ownership of Emergent BioSolutions Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001367644.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- EBS on NYSE
- Parsed ownership sources
- 13F and 13D/G
- Largest SEC-reported holder
- BlackRock, Inc.
- Latest 13D/G holder
- BlackRock, Inc.
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0001367644
- Issuer location
- Gaithersburg, MD
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Emergent BioSolutions Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
31 Mar 2026
13F
13D/G
Lead comparable stake: 7.3%
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 7.3%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
7.3%
DIMENSIONAL FUND ADVISORS LP
5.3%
STATE STREET CORP
5.1%
VANGUARD CAPITAL MANAGEMENT LLC
5%
AMERICAN CENTURY COMPANIES INC
4.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
7.3%
from 13D/G
|
$36,034,135
4,341,462 shares
|
— | 31 Mar 2026 |
| DIMENSIONAL FUND ADVISORS LP |
13D/G
13F
Company
|
5.3%
|
$22,887,169
2,757,158 shares
|
$0 | 31 Mar 2026 |
| STATE STREET CORP |
13D/G
13F
STATE STREET CORPORATION · Company
|
5.1%
|
$33,408,086
2,696,375 shares
|
$0 | 31 Dec 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5%
|
$21,622,247
2,605,090 shares
|
$0 | 31 Mar 2026 |
| AMERICAN CENTURY COMPANIES INC |
13F
Company
|
4.7%
|
$20,133,492
2,425,722 shares
|
— | 31 Mar 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
Company
|
2.9%
|
$12,500,423
1,506,075 shares
|
— | 31 Mar 2026 |
| ACADIAN ASSET MANAGEMENT LLC |
13F
Company
|
2.7%
|
$11,460,000
1,381,624 shares
|
— | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
2.5%
|
$10,567,751
1,272,909 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$1,524,984.
Buys
$0
Insiders: 0
Sells
$1,524,984
Insiders: 7
Net
-$1,524,984
Shares: -159,800
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 159,800
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 65,925 | $0 | $552,000 | -$552,000 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 78,945 | $0 | $842,300 | -$842,300 |
| 9-12 | 0 | 14,930 | $0 | $130,684 | -$130,684 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 27 reporting-owner rows connected to Emergent BioSolutions Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
27
Largest Forms 3/4/5 holder
Joseph C. Papa
Net 12M change
-$1,524,983
Latest report
30 Apr 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Joseph C. Papa | President and CEO, Director | $4,093,169 | Median | 29 Apr 2026 | ||
| Richard S. Lindahl | EVP, Chief Financial Officer | $3,137,790 | Median | 29 Apr 2026 | ||
| Fuad El-Hibri | Director | $2,444,997 | Mixed | 03 Dec 2021 | ||
| Coleen Glessner | EVP, Quality & Ethics, and CPL | $1,695,017 | -$306,080 | -15% | Median | 29 Apr 2026 |
| William Hartzel | SVP, Bioservices | $1,554,581 | Median | 29 Apr 2026 | ||
| Jennifer Lynne Fox | EVP, Ext Aff, GC, Corp Sec | $1,515,286 | Mixed | 11 Jul 2024 | ||
| Simon C. Lowry | Svp, R&D, Cmo | $1,476,686 | Median | 29 Apr 2026 | ||
| Jessica Perl | SVP, General Counsel, Corp Sec | $1,371,873 | Median | 29 Apr 2026 | ||
| Paul Anthony Williams | SVP, Products Business | $1,351,173 | -$33,760 | -2.4% | Median | 29 Apr 2026 |
| Neal Franklin Fowler | Director | $1,335,030 | Median | 30 Apr 2026 | ||
| Zsolt Harsanyi | Chairman, Director | $1,237,330 | Median | 30 Apr 2026 | ||
| Donald W. DeGolyer | Director | $1,162,300 | -$385,447 | -25% | Filing P/S | 30 Apr 2026 |
| Ronald Richard | Director | $1,027,216 | -$263,077 | -20% | Median | 30 Apr 2026 |
| Marvin L. White | Director | $944,863 | Median | 30 Apr 2026 | ||
| Robert Kramer | President and CEO, Director | $921,027 | Mixed | 09 Jun 2023 | ||
| Sujata Tyagi Dayal | Director | $899,033 | -$201,130 | -18% | Filing P/S | 30 Apr 2026 |
| Keith Katkin | Director | $797,314 | -$128,183 | -14% | Filing P/S | 30 Apr 2026 |
| Kathryn C. Zoon | Director | $717,070 | -$207,306 | -22% | Filing P/S | 30 Apr 2026 |
| Louis W. Sullivan | Director | $610,640 | Mixed | 30 Apr 2025 | ||
| Adam Havey | EVP, Business Operations | $317,404 | Mixed | 09 Jun 2023 |
Recent insider transactions for Emergent BioSolutions Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Sujata Tyagi Dayal | EBS | Common Stock | Sale | -12% | $115,610 | $8.40 | -13,761 | 100,563 | 01 May 2026 | Direct |
| Donald W. DeGolyer | EBS | Common Stock | Sale | -10.7% | $129,994 | $8.40 | -15,481 | 129,721 | 01 May 2026 | Direct |
| Kathryn C. Zoon | EBS | Common Stock | Sale | -17.7% | $144,453 | $8.40 | -17,202 | 79,941 | 01 May 2026 | Direct |
| Sujata Tyagi Dayal | EBS | Common Stock | Award | 28.5% | 25,344 | 114,324 | 30 Apr 2026 | Direct | ||
| Sujata Tyagi Dayal | EBS | Stock Option (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| Donald W. DeGolyer | EBS | Common Stock | Award | 21.2% | 25,344 | 145,202 | 30 Apr 2026 | Direct | ||
| Donald W. DeGolyer | EBS | Stock Option (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| Keith Katkin | EBS | Common Stock | Sale | -13.8% | $128,183 | $8.28 | -15,481 | 96,294 | 30 Apr 2026 | Direct |
| Keith Katkin | EBS | Common Stock | Award | 29.3% | 25,344 | 111,775 | 30 Apr 2026 | Direct | ||
| Keith Katkin | EBS | Stock Options (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| Marvin L. White | EBS | Common Stock | Award | 28.6% | 25,344 | 113,839 | 30 Apr 2026 | Direct | ||
| Marvin L. White | EBS | Stock Option (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| John D. Fowler Jr. | EBS | Common Stock | Award | 506.3% | 25,344 | 30,350 | 30 Apr 2026 | Direct | ||
| John D. Fowler Jr. | EBS | Stock Option (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| Ronald Richard | EBS | Common Stock | Award | 25.8% | 25,344 | 123,761 | 30 Apr 2026 | Direct | ||
| Ronald Richard | EBS | Stock Option (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| Kathryn C. Zoon | EBS | Common Stock | Award | 35.3% | 25,344 | 97,143 | 30 Apr 2026 | Direct | ||
| Kathryn C. Zoon | EBS | Stock Option (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| Neal Franklin Fowler | EBS | Common Stock | Award | 18.7% | 25,344 | 160,847 | 30 Apr 2026 | Direct | ||
| Neal Franklin Fowler | EBS | Stock Option (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| Zsolt Harsanyi | EBS | Common Stock | Award | 20.5% | 25,344 | 149,076 | 30 Apr 2026 | Direct | ||
| Zsolt Harsanyi | EBS | Stock Option (Right to Buy) | Award | 11,296 | 11,296 | 30 Apr 2026 | Direct | |||
| Paul Anthony Williams | EBS | Common Stock | Award | 159.7% | 100,111 | 162,792 | 29 Apr 2026 | Direct | ||
| Simon C. Lowry | EBS | Common Stock | Award | 128.7% | 100,111 | 177,914 | 29 Apr 2026 | Direct | ||
| Coleen Glessner | EBS | Common Stock | Award | 96.2% | 100,111 | 204,219 | 29 Apr 2026 | Direct | ||
| Richard S. Lindahl | EBS | Common Stock | Award | 75.5% | 162,680 | 378,047 | 29 Apr 2026 | Direct | ||
| Jessica Perl | EBS | Common Stock | Award | 170.9% | 104,282 | 165,286 | 29 Apr 2026 | Direct | ||
| William Hartzel | EBS | Common Stock | Award | 114.8% | 100,111 | 187,299 | 29 Apr 2026 | Direct | ||
| Joseph C. Papa | EBS | Common Stock | Award | 61.4% | 187,708 | 493,153 | 29 Apr 2026 | Direct | ||
| Paul Anthony Williams | EBS | Common Stock | Sale | -6% | $33,760 | $8.44 | -4,000 | 62,681 | 01 Apr 2026 | Direct |
| Joseph C. Papa | EBS | Common Stock | Tax liability | -10.8% | -37,055 | 305,445 | 05 Mar 2026 | Direct | ||
| Simon C. Lowry | EBS | Common Stock | Tax liability | -12% | -10,636 | 77,803 | 05 Mar 2026 | Direct | ||
| William Hartzel | EBS | Common Stock | Tax liability | -9.82% | -9,493 | 87,188 | 05 Mar 2026 | Direct | ||
| Jessica Perl | EBS | Common Stock | Tax liability | -9.58% | -6,465 | 61,004 | 05 Mar 2026 | Direct | ||
| Paul Anthony Williams | EBS | Common Stock | Tax liability | -12.4% | -9,397 | 66,681 | 05 Mar 2026 | Direct | ||
| Richard S. Lindahl | EBS | Common Stock | Tax liability | -9.89% | -23,650 | 215,367 | 05 Mar 2026 | Direct | ||
| Coleen Glessner | EBS | Common Stock | Tax liability | -7.3% | -8,199 | 104,108 | 05 Mar 2026 | Direct | ||
| Joseph C. Papa | EBS | Employee Stock Option (Right to buy) | Award | 16.5% | 252,194 | 1,784,694 | 03 Mar 2026 | Direct | ||
| John D. Fowler Jr. | EBS | Common Stock | Award | 5,006 | 5,006 | 03 Mar 2026 | Direct | |||
| Simon C. Lowry | EBS | Employee Stock Option (Right to buy) | Award | 43.5% | 44,834 | 147,833 | 03 Mar 2026 | Direct | ||
| William Hartzel | EBS | Employee Stock Option (Right to buy) | Award | 20.9% | 44,834 | 259,545 | 03 Mar 2026 | Direct | ||
| Jessica Perl | EBS | Employee Stock Option (Right to buy) | Award | 48.7% | 46,702 | 142,647 | 03 Mar 2026 | Direct | ||
| Paul Anthony Williams | EBS | Employee Stock Option (Right to buy) | Award | 21.3% | 44,834 | 254,948 | 03 Mar 2026 | Direct | ||
| Richard S. Lindahl | EBS | Employee Stock Option (Right to buy) | Award | 15% | 72,856 | 557,346 | 03 Mar 2026 | Direct | ||
| Coleen Glessner | EBS | Employee Stock Option (Right to buy) | Award | 18% | 44,834 | 294,447 | 03 Mar 2026 | Direct | ||
| Paul Anthony Williams | EBS | Common Stock | Tax liability | -0.15% | -116 | 76,078 | 01 Mar 2026 | Direct | ||
| Richard S. Lindahl | EBS | Common Stock | Tax liability | -0.28% | -683 | 239,017 | 01 Mar 2026 | Direct | ||
| Coleen Glessner | EBS | Common Stock | Tax liability | -0.28% | -313 | 112,307 | 01 Mar 2026 | Direct | ||
| Richard S. Lindahl | EBS | Employee Stock Option (Right to buy) | Expiration (or cancellation) of long derivative position with value received | -100% | -20,321 | 0 | 25 Feb 2026 | Direct | ||
| Jessica Perl | EBS | Common Stock | Tax liability | -1.34% | -918 | 67,469 | 09 Feb 2026 | Direct |
* marks a reported price that did not pass the local price check.